Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Michael Goodman
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.
Advances in computational power and in the application of quantum mechanics to drug modeling are rekindling interest in in silico drug design. The prize is a steep reduction in the cost of discovery and an increase in the quality of lead candidates.
The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
Tumor necrosis factor-related apoptosis-inducing ligand has been a tantalizing cancer target since it was first cloned and characterized 20 years ago, but the performance of TRAIL agonists in the clinic over the past decade, all of them antibodies, has been disappointing. Now Oncoceutics Inc. may be on the verge of reviving the promise of TRAIL with a small molecule that works by triggering a cascade of tumor suppressing pathways.